Summary
Obstructive sleep apnea (OSA) is a highly prevalent disorder characterized by episodes of decreased or absent inspiratory airflow during sleep. OSA is the world’s second-most common sleep disorder, plaguing over 1 billion patients worldwide with relentless, disruptive periods of restricted airflow during sleep. This can have dramatic effects, ranging from excessive daytime sleepiness to other comorbidities such as stroke, hypertension or depression. The effects of this disorder are pervasive and far-reaching, as diminished sleep quality eventually reduces general quality of life. Positive airway pressure (PAP) delivered through a tight-fitting mask is currently the most advanced technique for preventing airway collapse or airway narrowing during sleep, and is considered the primary treatment option for patients with moderate to severe OSA. However, despite improvements in quieter pumps and more comfortable masks, this approach has several disadvantages and patients very often struggle to comply with the therapy. We have recently shown that a non-invasive form of HNS can be effective in treating OSA patients by using temporal interference (TI) , a new non-invasive electrical stimulation technology which has been successfully advanced also for other clinical applications by the PI. Our device revolutionizes sleep apnea treatment with the efficacy of upper airway stimulation, without requiring surgery. Our proprietary new technology generates comfortable electrical fields which activate the tongue muscle and open airways. Its effectiveness is comparable to the best in market, while remaining non-invasive and financially accessible. FitSleep is an essential part of our exploitation strategy, which will ensure we advance the technology from TRL4 (currently) to TRL5. This will give us an ideal position for a subsequent EIC Transition application.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101157945 |
| Start date: | 01-05-2024 |
| End date: | 31-10-2025 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
Obstructive sleep apnea (OSA) is a highly prevalent disorder characterized by episodes of decreased or absent inspiratory airflow during sleep. OSA is the world’s second-most common sleep disorder, plaguing over 1 billion patients worldwide with relentless, disruptive periods of restricted airflow during sleep. This can have dramatic effects, ranging from excessive daytime sleepiness to other comorbidities such as stroke, hypertension or depression. The effects of this disorder are pervasive and far-reaching, as diminished sleep quality eventually reduces general quality of life. Positive airway pressure (PAP) delivered through a tight-fitting mask is currently the most advanced technique for preventing airway collapse or airway narrowing during sleep, and is considered the primary treatment option for patients with moderate to severe OSA. However, despite improvements in quieter pumps and more comfortable masks, this approach has several disadvantages and patients very often struggle to comply with the therapy. We have recently shown that a non-invasive form of HNS can be effective in treating OSA patients by using temporal interference (TI) , a new non-invasive electrical stimulation technology which has been successfully advanced also for other clinical applications by the PI. Our device revolutionizes sleep apnea treatment with the efficacy of upper airway stimulation, without requiring surgery. Our proprietary new technology generates comfortable electrical fields which activate the tongue muscle and open airways. Its effectiveness is comparable to the best in market, while remaining non-invasive and financially accessible. FitSleep is an essential part of our exploitation strategy, which will ensure we advance the technology from TRL4 (currently) to TRL5. This will give us an ideal position for a subsequent EIC Transition application.Status
SIGNEDCall topic
ERC-2023-POCUpdate Date
24-11-2024
Images
No images available.
Geographical location(s)
